Novo Nordisk A/S won approval to sell a high-dose version of its blockbuster Wegovy obesity shot in the US, allowing it to offer weight loss closer to Eli Lilly & Co.’s rival Zepbound. Novo will start ...
(Bloomberg) -- Novo Nordisk A/S’s next-generation obesity shot delivered less weight loss than Eli Lilly & Co.’s rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ...
Novo Nordisk and Eli Lilly make the world’s top-selling weight loss drugs. These products have driven the companies’ revenue growth in recent years. Investors generally buy pharmaceutical stocks to ...
Novo Nordisk remains a compelling long-term healthcare compounder, despite mixed Q3 results and recent stock weakness. NVO's growth is driven by global obesity drug demand, robust pipeline development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results